Bladder Cancer Roundup: Enfortumab Vedotin, Nivolumab, and More

By Petros Grivas, MD, PhD - Last Updated: June 12, 2024

Petros Grivas, MD, PhD, of Fred Hutchinson Cancer Center, provides an update on relevant clinical trial updates and data readouts pertaining to urothelial carcinoma from the 2024 American Society of Clinical Oncology Annual Meeting.

View his continued comments on JAVELIN Bladder 100 Long-Term Data: Patients With Histological Subtypes, Low Tumor Burden.

Pioneering Advances in Bladder Cancer: New Drug Classes, Biomarkers, and Treatment Models

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.

Utility of ctDNA, Overcoming Barriers to Multidisciplinary Care in Community, Academic Settings

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 21, 2025

The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.

Bladder-Sparing with Systemic Therapy: Insights from RETAIN-2 and Future Directions

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.

Post-EV/Pembro Progression: How Real-World Data is Shaping 2L Treatment Decisions

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.

Balancing EV/Pembro and Gem/Cis-Nivo: Selecting the Right 1L Therapy for Node-Only Disease

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.

Bladder Cancer Roundup: Enfortumab Vedotin, Nivolumab, and More

Related Posts